Studies Shed Light on Hepatitis C Virus Sexual Transmission among Gay Men

Hepatitis C virus (HCV) transmission among HIV positive gay men has leveled off in Amsterdam -- one of the first cities with an outbreak of apparently sexually transmitted HCV infection -- and it continues to be rare among HIV negative men who have sex with men, according to recent studies. Other research looked at HCV sexual transmission among HIV positive and negative men in Switzerland, and at the association between HCV viral load in blood and semen.

alt

Read more:

DDW 2014 and EASL 2014: Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis

The antibiotic rifaximin may help prevent or improve hepatic encephalopathy and bleeding varices in people with decompensated liver disease, according to studies presented at the recent EASL International Liver Congress and Digestive Disease Week.

alt

Read more:

EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies

Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.

alt

Read more:

CROI 2014 & EASL 2014: Treating Hepatitis B and C in HIV+ People Reduces Liver Disease

Effective antiviral treatment that suppresses hepatitis B virus (HBV) repliaction or eradicates hepatitis C virus (HCV) can lower the risk of developing advanced liver disease including cirrhosis, hepatocellular carcinoma, and decompensation in people with HIV and viral hepatitis coinfection, according to studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) and EASL International Liver Congress.

alt

Read more:

EASL 2014: Long-term Tenofovir Maintains Viral Suppression in People with Hepatitis B

Treatment with tenofovir (Viread) for 3 years remained effective in keeping hepatitis B virus (HBV) suppressed, normalizing liver inflammation, and potentially reducing liver disease progression, according to studies from Germany, France, and Spain presented at the 49thEASL International Liver Congress (EASL 2014) recently held in London.

alt

Read more:

More Articles...